Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Immunotherapy|April 5, 2019
Post-shingles granulomatous dermatosis related to anti-programmed cell death 1Tarek Assi, Alina Danu, Christine Mateus, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2021
Reduced frequency of cytotoxic CD56<sup>dim</sup> CD16<sup>+</sup> NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphomaElena Pánisová, Anna Lünemann, Simone Bürgler, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphomaLaurent Dercle, Samy Ammari, Romain-David Seban, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2017
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphomaJulien Lazarovici, Marie Terroir, Julia Arfi-Rouche, et al.
European Journal of Haematology|January 29, 2021
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapyPamela Abdayem, Nathalie Ibrahim, Yolla El Dakdouki, et al.
Cancers|November 13, 2021
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 ImmunotherapyJean-Marie Michot, Severine Mouraud, Julien Adam, et al.
Cancer Medicine|April 7, 2020
Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomasKhalil Saleh, Jean-Marie Michot, Antoine Schernberg, et al.
European Journal of Haematology|December 16, 2019
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II resultJean-Marie Michot, Maxime Annereau, Alina Danu, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphomaJean-Marie Michot, Alice Buet-Elfassy, Maxime Annereau, et al.
Leukemia & Lymphoma|November 23, 2017
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experienceKhalil Saleh, Alina Danu, Serge Koscielny, et al.
Pageof 5